Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2B, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rencofilstat in Adult Subjects With Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis

NCT05402371 is registered in ClinicalTrials.gov with Hepion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05402371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05402371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2B, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rencofilstat in Adult Subjects With Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis
Lead sponsor
Hepion Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
October 15, 2022
Completion date
September 30, 2025
Enrollment
120 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

fibrosis, liver, nafld, nonalcoholic steatohepatitis (nash)